Skip to content

Genpact G Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Cognizant logo
CognizantCTSH
Gartner logo
GartnerIT
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG

Other financials

Income statement

See full
Revenue$1.3B+6.7%
Gross profit$471.7M+9.9%
Operating income$198.6M+8.1%
Net income$148.0M+13.1%
EPS (diluted)$0.86+17.8%

Balance sheet

See full
Cash & equivalents$578.1M+2.9%
Total debt$1.4B-4.9%
Total equity$2.5B+0.9%
Total assets$5.6B+14.8%

Cash flow

See full
Operating cash flow-$23.5M-158%
CapEx$23.9M+8.9%
Free cash flow-$47.5M-357%

Valuation

See full
Market cap$4.79B-28.5%

Profitability

See full
Gross margin36.3%+0.8pp
Operating margin14.8%-0.1pp
Net margin11%+0.2pp
FCF margin13%+0.6pp

Returns & leverage

See full
Return on equity23.1%+0.9pp
Debt / equity0.6×0.0×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Genpact in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Genpact’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Genpact's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Genpact's proceeds from exercises of stock options and other stock issuances?
Genpact (G) reported proceeds from exercises of stock options and other stock issuances of $2.82M in Q1 2026.
How has Genpact's proceeds from exercises of stock options and other stock issuances changed year-over-year?
Genpact's proceeds from exercises of stock options and other stock issuances decreased by 59.4% year-over-year, from $6.94M to $2.82M.
What is the long-term trend for Genpact's proceeds from exercises of stock options and other stock issuances?
Over 4 years (2021 to 2025), Genpact's proceeds from exercises of stock options and other stock issuances has grown at a -15.9% compound annual growth rate (CAGR), from $35.05M to $17.51M.